CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer
“Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.
- “Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.
- “This guideline is intended to provide an overview of the clinical rationale for the use of PD-L1 and tumor mutational burden (TMB) testing for patients with non-small lung cancer.
- With six recommendations, the guideline provides data and details regarding the efficacy and utility of PD-L1 testing of patients with lung cancer.
- Current tools, resources, and information for the PD-L1 Testing of Patients with Lung Cancer Guideline can be found on the guideline webpage on cap.org.